 Connection
Eric Wu to Hepatitis C, Chronic
This is a "connection" page, showing publications Eric Wu has written about Hepatitis C, Chronic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.913 |
|
|
|
-
Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ. Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States. Clin Ther. 2015 Aug; 37(8):1713-25.e3.
Score: 0.394
-
Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ. Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir. J Manag Care Spec Pharm. 2015 Apr; 21(4):308-18.
Score: 0.388
-
Welzel TM, Yang M, Sajeev G, Chen YJ, Pinsky B, Bao Y, Wu EQ, Dieterich D. Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections. Adv Ther. 2019 09; 36(9):2475-2486.
Score: 0.130
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|